What Liquid Cartilage™ actually is

Liquid Cartilage™ is the name Lincolnshire Hip Clinic uses for ChondroFiller® injections into the hip joint. Behind the brand name sits a CE-marked Class III medical device — a solution of murine-derived Type I collagen placed directly into the damaged joint under ultrasound guidance as an outpatient procedure.

The mechanism begins the moment the collagen solution meets the joint's natural fluid and fibrin: within three to five minutes it hardens into a viscoelastic gel, settling as a protective scaffold over the worn cartilage surface. Rather than removing damaged tissue surgically, the scaffold acts as an additive layer — a top-down cushion applied over the damaged surface rather than an excavation from below.

What makes the approach regenerative is what happens next. The gel provides a chemotactic matrix — a biological signal that draws the patient's own progenitor cells in from the surrounding synovium and subchondral bone. Over the following weeks those cells migrate into the scaffold and mature into chondrocyte-like cells capable of producing cartilage tissue. By 12 months the defect progressively fills with the patient's own regenerated tissue; by one to two years the collagen scaffold has been fully resorbed, leaving no foreign material in the hip joint.

This is the basis for describing Liquid Cartilage™ as supporting the body's own repair processes rather than simply filling the joint — a distinction that shapes both patient selection and recovery expectations, and one that depends on accurate, image-guided placement to deliver the collagen to precisely the right site.

Why the hip joint loses cartilage and becomes stiff

The hip joint relies on a layer of smooth, low-friction cartilage to allow pain-free movement through its full range. That cartilage can thin or wear away for several reasons: age-related degeneration, osteoarthritis, femoroacetabular impingement (FAI — where an abnormal bone shape causes repeated contact and cartilage wear), sports injuries, falls, or the cumulative effect of repetitive loading.

Once cartilage thins, the joint space narrows and friction rises. The hip loses its normal glide, and movement that was once effortless becomes stiff — particularly on first rising in the morning or after prolonged sitting. Left unaddressed, continued loss eventually brings bone into contact with bone.

Early-to-moderate damage is a clinically distinct stage from end-stage arthritis. The joint still has meaningful cartilage and preserved architecture — the conditions in which repair-supporting treatments may have most to offer. Intra-articular injections as a class have randomised trial support for reducing pain and improving hip function in this context; that evidence covers a range of agents including hyaluronic acid, corticosteroid, and collagen-scaffold products, rather than any single agent in isolation.

Hip stiffness does have more than one cause. Cartilage loss produces a particular pattern — progressive restriction across multiple planes of movement — that differs from the localised tenderness of bursitis or the snapping discomfort of a tendinous problem. Clarifying the source through clinical assessment and imaging is the necessary starting point before any injection pathway is considered.

Who this treatment is — and isn't — for

Not every patient presenting with hip stiffness will be a candidate for Liquid Cartilage™ — and Professor Lee's starting point at consultation is an honest assessment of where a patient actually sits, rather than a sales process.

The injection is best suited to early-to-moderate hip cartilage damage: joints that retain meaningful cartilage and preserved architecture, where the body's own repair capacity can be recruited by the scaffold. Typical candidates include patients whose stiffness stems from FAI, a sports or trauma injury, repetitive loading, or age-related wear — but whose joint has not yet reached end-stage destruction.

Patients with advanced Kellgren-Lawrence Grade IV osteoarthritis, where significant joint space has already been lost, are better served by hip replacement. Lincolnshire Hip Clinic offers both pathways; the purpose of the initial consultation is to determine which one applies rather than to fit every patient into an injection programme.

A simple way to frame the decision ladder: conservative physiotherapy and analgesia sit at one end; hip replacement surgery at the other. Liquid Cartilage™ occupies the middle ground — for patients who have moved beyond what physiotherapy alone can achieve but who are not yet at the stage where replacement is the appropriate answer.

Liquid Cartilage™ is available on a self-funded basis only. It is not reimbursed by the NHS or by private medical insurance, and this should be factored into any treatment decision. The cost at Lincolnshire Hip Clinic is £2,995 per injection.

What the appointment involves at Lincolnshire Hip

For Lincolnshire patients, the treatment pathway — consultation, injection, and follow-up — runs entirely through local clinics in Grantham and Sleaford. No trip to London is required at any stage.

The appointment itself is an outpatient procedure. There is no surgical incision, no theatre admission, and no general anaesthetic. Professor Paul Lee — FRCS(Tr & Orth), PhD, and the first clinician in the UK to offer ChondroFiller® as an injection — uses real-time ultrasound throughout to guide accurate placement of the collagen solution into the hip joint. This image-guided approach is clinically important: ChondroFiller® is a technique-sensitive treatment, and precise intra-articular delivery is central to how it works.

IV antibiotic cover is included as standard during the appointment. Local anaesthetic is used to keep the procedure comfortable. The collagen gel stabilises within a few minutes of injection, and the appointment itself fits within a single outpatient slot — no overnight admission, no surgical wound care on discharge.

The £2,995 fee covers the complete episode of care at the clinic: the collagen matrix dose, ultrasound-guided delivery by Professor Lee, IV antibiotic cover, and a local follow-up appointment. Each of those components is included in that single figure, with no separate charges for the elements delivered during the appointment.

Recovery and what to expect over the following months

Recovery splits into two distinct phases, each with a clear purpose that patients can map onto their own calendar.

Weeks 1–6: protecting the scaffold

In the first six weeks, the priority is letting the collagen gel stabilise undisturbed. Hip loading is kept limited and movement is controlled — enough to guard against stiffness, but not so much as to disturb the newly placed matrix. This is not passive rest; it is a deliberate protection window that gives the body's own cells time to begin migrating into the scaffold and establishing themselves.

Weeks 7–12: rebuilding strength

From around week seven, the focus shifts to structured physiotherapy aimed at restoring hip muscle strength and joint stability. The supporting structures around the hip are progressively loaded as the joint responds, with low-impact activity introduced in a graded way under physiotherapy guidance.

Structural and functional changes over 12 months

Post-treatment MRI studies document the biological changes taking place beneath the surface: measurable reductions in bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space. Alongside these structural findings, patient-reported outcome data using hip-specific measures show approximately 30-point improvements at 12 months — a clinically meaningful shift in pain and function that reflects progressive tissue maturation continuing well into the second year.

Evidence, honest caveats, and how to find out if it's right for you

ChondroFiller® carries a CE mark as a Class III medical device — the EU's highest classification, reserved for devices that interact directly with the body at a functional level — and published clinical data documents an adverse event rate of approximately 0.06%, which is notably low for an intra-articular intervention.

Imaging outcomes in available studies show MOCART scores — a validated measure of cartilage fill quality on MRI — typically ranging from 70 to 87 at follow-up. Those figures indicate substantial defect fill, and they correspond with the structural MRI responses noted in post-treatment data: reduced bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space.

The evidence gap patients should weigh honestly is this: the bulk of published outcome data — including most RCT-level studies — comes from knee applications rather than the hip. Hip-specific evidence is less extensive, and what exists includes manufacturer-sponsored clinical evaluation material and post-treatment imaging findings rather than large independent randomised trials in the hip. That is not uncommon across the intra-articular injection landscape, but it is worth naming plainly rather than papering over.

What that means in practice is that suitability cannot be read off a dataset alone — it requires mapping the available evidence against an individual's imaging, symptom pattern, and stage of cartilage loss. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.